These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7060036)

  • 21. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal failure in multiple myeloma. A study of the presenting findings, response to treatment and prognosis in 26 patients.
    Cavo M; Baccarani M; Galieni P; Gobbi M; Tura S
    Nouv Rev Fr Hematol (1978); 1986; 28(3):147-52. PubMed ID: 3748798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
    J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NTP Toxicology and Carcinogenesis Studies of Dimethyl Methylphosphonate (CAS No. 756-79-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1987 Nov; 323():1-172. PubMed ID: 12748730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of multiple myeloma with melphalan: 35 personal cases].
    Dryll A; Ryckewaert A; Kahn MF; Hayat M; de Seze S
    Sem Hop; 1970 Jan; 46(5):289-98. PubMed ID: 4327260
    [No Abstract]   [Full Text] [Related]  

  • 29. NTP Toxicology and Carcinogenesis Studies of Tetrafluoroethylene (CAS No. 116-14-3) in F344 Rats and B6C3F1 Mice (Inhalation Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1997 Apr; 450():1-321. PubMed ID: 12594525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
    Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
    Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel RJ
    Invest New Drugs; 1987; 5 Suppl():S41-6. PubMed ID: 3597002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure.
    Tauro S; Clark FJ; Duncan N; Lipkin G; Richards N; Mahendra P
    Bone Marrow Transplant; 2002 Oct; 30(7):471-3. PubMed ID: 12368962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents.
    Ringborg U; Lewensohn R
    Acta Med Scand; 1978; 203(4):276-8. PubMed ID: 645439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
    Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma.
    Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Rigg A; Horton C; Singhal S; Mehta J; Treleaven J
    Br J Cancer; 2001 Aug; 85(3):325-32. PubMed ID: 11487259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NTP Toxicology and Carcinogenesis Studies of Oxymetholone (CAS NO. 434-07-1) in F344/N Rats and Toxicology Studies of Oxymetholone in B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Aug; 485():1-233. PubMed ID: 12571678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
    Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
    Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicology and Carcinogenesis Studies of Mercuric Chloride (CAS No. 7487-94-7) in F344 Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Feb; 408():1-260. PubMed ID: 12621522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
    Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
    Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.